Results 201 to 210 of about 27,184 (256)

Weight changes and adverse pregnancy outcomes with dolutegravir- and tenofovir alafenamide fumarate-containing antiretroviral treatment regimens during pregnancy and postpartum.

Clinical Infectious Diseases
BACKGROUND We evaluated associations between antepartum weight change and adverse pregnancy outcomes and between antiretroviral therapy (ART) regimens and week-50 postpartum body mass index in IMPAACT 2010.
Risa M Hoffman, S. Brummel, L. Ziemba, L. Chinula, K. McCarthy, L. Fairlie, P. Jean‐Philippe, N. Chakhtoura, Benjamin Johnston, Chelsea Krotje, Teacler Nematadzira, Frances Nakayiwa, Victoria Ndyanabangi, S. Hanley, Gerhard B. Theron, A. Violari, E. Joao, M. C. Corrêa Júnior, C. B. Hofer, Oranich Navanukroh, L. Aurpibul, Neetal Nevrekar, Rebecca Zash, Roger Shapiro, Jeffrey S A Stringer, Judith S Currier, Paul E. Sax, S. Lockman   +27 more
semanticscholar   +1 more source

Integrase strand transfer inhibitor resistance mediated by R263K plus E157Q in a patient with HIV infection treated with bictegravir/tenofovir alafenamide/emtricitabine: case report and review of the literature.

Journal of Antimicrobial Chemotherapy
OBJECTIVES The in vivo selection of E157Q plus R263K has not been reported in patients treated with coformulated bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF).
L. Buzón-Martín, Carolina Navarro-San Francisco, María Fernández-Regueras, Leticia Sanchez-Gomez   +3 more
semanticscholar   +1 more source

Weight and Metabolic Changes With Long-Acting Cabotegravir and Rilpivirine or Bictegravir/Emtricitabine/Tenofovir Alafenamide

Journal of Acquired Immune Deficiency Syndromes
Supplemental Digital Content is Available in the Text. Background: Modest weight and lipid changes have been observed in cabotegravir plus rilpivirine long-acting (CAB + RPV LA) phase 3/3b studies.
Darrell H. S. Tan, A. Antinori, B. Eu, M. J. Galindo Puerto, Clifford Kinder, Donna Sweet, Cornelius N Van Dam, K. Sutton, Denise Sutherland-Phillips, Alessandro Berni, Feifan Zhang, R. Urbaityte, Bryan Baugh, W. Spreen, J. van Wyk, H. Garges, P. Patel, Rachel L Batterham, Ronald D'Amico   +18 more
semanticscholar   +1 more source

Comparative efficacy and safety of tenofovir amibufenamide vs tenofovir alafenamide in the initial 48-week treatment of high viral load chronic hepatitis B: A single-centre retrospective study

Antiviral Therapy
Background/aim Tenofovir amibufenamide (TMF) employs innovative ProTide technology and a methylation strategy to enhance the lipid solubility and plasma stability of the amide bond, providing advantages over tenofovir alafenamide (TAF). Despite promising
Qing Zhang, Jianhua Xu, Dan Liu, Lilin Wang, S. Ren, Sujun Zheng, Xinyue Chen, Li Qi, Junfeng Lu   +8 more
semanticscholar   +1 more source

Pharmacokinetic evaluation of bictegravir + emtricitabine + tenofovir alafenamide in HIV treatment

Expert Opinion on Drug Metabolism & Toxicology
Introduction The combination of bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF) represents a valid option of antiretroviral therapy (ART) as first line regimen both in ART-naïve and -experienced people with HIV (PWH).
E. Bruzzesi, C. Muccini, Antonella Castagna   +2 more
semanticscholar   +1 more source

Tenofovir-Diphosphate and Emtricitabine-Triphosphate Adherence Benchmarks in Dried Blood Spots for Persons with HIV Receiving Tenofovir Alafenamide and Emtricitabine-based Antiretroviral Therapy (QUANTI-TAF).

Clinical Infectious Diseases
BACKGROUND QUANTI-TAF aimed to establish tenofovir-diphosphate/emtricitabine-triphosphate (TFV-DP/FTC-TP) adherence benchmarks in dried blood spots (DBS) for persons with HIV (PWH) receiving tenofovir alafenamide/emtricitabine (TAF/FTC)-based ...
Ryan P Coyle, Mary Morrow, Sarah C Mann, Vincent Mainella, Samuel L. Ellis, Stefanie Schwab, Corwin Coppinger, Nicholas Barker, L. Ellison, Jia-Hua Zheng, Subhi Al Zuabi, Pamela E Alpert, T. C. Carnes, D. E. Buffkin, Peter R. Chai, Lane R. Bushman, J. Kiser, Samantha MaWhinney, Kristina M. Brooks, P. Anderson, J. Castillo-Mancilla   +20 more
semanticscholar   +1 more source

Efficacy and Safety of Tenofovir Amibufenamide and Tenofovir Alafenamide for First‐Time HBV‐Related Decompensated Cirrhosis

Journal of Viral Hepatitis
Clinical studies of tenofovir amibufenamide (TMF) and tenofovir alafenamide (TAF) treatment in patients with HBV‐related decompensated cirrhosis (HBV‐DC) are limited.
Xinxin Rong, Guangde Yang, Yuanyuan Xu, He Chen, Xia Wang, Juanjuan Fu, Li Li, Xiucheng Pan   +7 more
semanticscholar   +1 more source

Comparative evaluation of adverse drug reactions for tenofovir alafenamide and tenofovir disoproxil fumarate using the FAERS Database: a disproportionality analysis

Expert Opinion on Drug Safety
Background Tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) are widely used nucleoside reverse transcriptase inhibitors (NRTIs), necessitating a thorough understanding of their safety profiles to ensure optimal patient care and ...
Meng Zhu, Lingjuan Jia, Yike Wang, yongsheng Zhang, Shengxia Lv   +4 more
semanticscholar   +1 more source

Tenofovir alafenamide

Reactions Weekly, 2018
openaire   +2 more sources

Tenofovir alafenamide

Reactions Weekly, 2023
openaire   +1 more source